

Original Research Article

TO ASSESS THE ROLE OF NIMESULIDE IN THE TREATMENT OF COVID-19 INFECTION

ABSTARCT

Objective: There are different anti-inflammatory drugs that are being used in patients with moderate to severe COVID-19 infection. However, in mild to moderate COVID-19 infection, Nimesulide treatment might impede the inflammation with a superior safety profile. Therefore this study was intended to assess the anti-inflammatory, analgesic and antipyretic activity of nimesulides in mild to moderate Covid-19 infection.

Methodology: This was an uncontrolled longitudinal study conducted at Pakistan Institute of Medical Sciences Islamabad. The duration of the study was about six months. A total of 66 patients were enrolled. All the patients received nimesulide 100 mg along with 10 ml sucralfate suspension two times a day for five days. Patients with elevated C-reactive protein or further comorbidities were prescribed 250 mg azithromycin two times a day for five days. Patients with elevated D-dimer (above 500) or other comorbidities were prescribed enoxaparin in a dose of 60 mg subcutaneously once daily for five days. The Primary outcome was estimated in terms of a percent change in oxygen saturation, hospitalization, or death.

Results: The results showed that 31(47.0%) were females and 35(53.0%) were males. The mean oxygen saturation on presentation was $93\% \pm 7.9$. 24(36.36%) of the patients had D-dimer levels < 250 ng/ml, while 30(45.45%) of the patients had D-dimer levels > 250 ng/ml with significant difference between them ($p=0.025$). 16(24.24%) patients received enoxaparin while 49(74.24%) patients did not received enoxaparin and found a significant difference between the mean change in oxygen saturation of them ($p<0.001$). 47(71.2%) patients received azithromycin while 19(28.8%) patients did not received azithromycin and found a significant difference between the mean change in oxygen saturation of them ($p=0.03$).

Conclusion: This study concluded that Nimesulide treatment resulted in a rapid temperature fall within five days. Furthermore, oxygen saturation was also significantly improved in patients treated with nimesulide.

Keywords: Nimesulide, mild to moderate Covid-19 infection, azithromycin, enoxaparin

INTRODUCTION

Globally, the COVID-19 disease is a main concern about public health, still no medication or vaccines for protection and treatment have been accepted until now, excluding remdesivir that has been currently approved for use in the Japan and USA [1]. COVID-19 presents in changeable phases of patient outcomes that ranges from mild, moderate to severe infection [2]. Though, management of mild/asymptomatic patients occur by isolation at home along with self-medication, moderately ill patients need hospitalization whereas severely infected COVID-19 patients remain need hospitalization with intensive care.[3] Due to the variety of comorbidities and complications in the badly affected patients and the devastating rapidity of the virulent disease, the schedule of medications in COVID-19 critical care is yet to be consistent.[4]

A lot of clinical researches are continuing. Most of the antiviral and antimalarial medicines for instance lopinavir/ritonavir, and chloroquine (CQ) or hydroxychloroquine (HCQ) derivatives that have revealed antiviral function against SARS-CoV-2 in vitro[5]. As SARS coronavirus diseases are recognized to provoke inflammatory process followed by damage of lung tissues in moderate-to-severe infections [6], it is predicted that Immunomodulatory drugs might give advantage in the management of COVID-19 infections.

However, Nimesulide (N-[4-nitro-2-phenoxyphenyl]-methanesulfonamide) is a therapeutically applicable non-steroidal anti-inflammatory drug (NSAID) (7). Clinically, this group of medicines has been generally applied as it possess anti-inflammatory, analgesic and antipyretic activities.(8) As far as the side effects are concerned, most commonly observed side effect of NSAIDs are liver toxicity that has been frequently related to their uncoupling effects on mitochondria (9). Owing to risk of Hepatotoxicity, nimesulide has been unavailable in the marketplace in many nations such as Belgium, Spain, Finland, United States and Ireland.[10]

Alarming issue has been created that NSAIDs could be linked to raised chances of undesirable effects particularly used in acute viral respiratory infections as well as in COVID-19 disease.[11] Therefore, there is a need to discover drugs with the most significant immunomodulatory functions. Hence, antibacterial macrolide such as azithromycin (AZM) has a unique and remarkable status in this regard for treatment of COVID-19 infections. It has been explored that AZM has considerable antiviral activities. Its antiviral function has been revealed in opposition to a huge group of viruses' for instance respiratory syncytial virus, Ebola, Zika, influenzae H1N1 virus, rhinovirus, and enterovirus[12-16]. Its antiviral function in opposition to respiratory syncytial virus has been described in a randomized trial in newborn babies [17]. Azithromycin possessed a synergistic antiviral activity against SARS-CoV-2 as in combination with HCQ both in a clinical site [18] and in vitro [19]. Azithromycin has additional striking therapeutic role along with pharmacological characteristics in the exploration for COVID-19 treatment. It is widely dispersed in lung tissues showing higher average concentrations in both intracellular and extracellular fluids than in plasma [20]

Other complications that are associated with COVID-19 infections are Coagulopathies [21], predominantly in critical situations of infection [22]. One of the study determined hematological factors in COVID-19 infections [23]. Researches that are comparing anticoagulation treatments are continuing, though due to the extensive prevalence and severe infection, it is imperative to assess the more observational facts to quickly create proof to direct the treatment [24]. A broad variety of anticoagulants like Enoxaparin, unfractionated Heparin, and Rivaroxaban are being applied in management of COVID-19 patients according to requirement [25]. One of the study reported that the standardized-dosage of Enoxaparin enhances survival rate and diminishes hospitalizations in advanced age of > 50 years in symptomatic ambulatory cases [26].

Multiple studies have been conducted internationally to identify the treatment of Covid 19 infection but it is still a matter of debate. Therefore, this study was intended to assess the effects of nimesulide in Covid-19 patients.

METHODOLOGY

This was an uncontrolled longitudinal study conducted at Pakistan Institute of Medical Sciences Islamabad by using consecutive sampling technique. The duration of the study was about six

months. A total of 66 patients were enrolled for this study after taking the ethical approval by the ethical committee.

The inclusion criteria involved Adults' ≥ 12 years who were not formerly diagnosed or treated for COVID-19 infection were included in the study. Patients who were sensitive to any of the study group, patients who had contraindications to any of the medicines, active bleeding, having past history of myocardial infarction, Peptic ulcer disease, already taking an NSAID or Nimesulide, unable to follow up for the trial period were excluded from the study.

All the patients received Nimesulide 100 mg two times a day for five days along with 10 ml sucralfate suspension two times a day for five days. Patients with elevated C-reactive protein or further comorbidities were prescribed 250 mg azithromycin two times a day for five days. Patients with elevated D-dimer test (over 500) or other comorbidities were prescribed enoxaparin in a dose of 60 mg subcutaneously once daily for five days.

All patients were assessed for baseline spO_2 and a chest X-ray that was repeated following 5 days. The Primary outcome was estimated in terms of a percent change in oxygen saturation, hospitalization, or death. Secondary outcomes involved symptomatic improvement of fever following initiation of treatment and any reporting of undesirable side effects by the patients.

Data was entered and analyzed by using SPSS version 22. The continuous variables such as age, TLC, D-dimer and CRP were estimated as means whereas categorical variables like gender, other comorbidities, and radiological findings were presented in percentages and frequencies. Chi-square test and T-test were applied to assess the significance. P value of <0.05 was considered as significant.

RESULT

A total of 66 patients were selected for the study, wherein 31(47.0%) of the study patients were females and 35(53.0%) were males. The mean age of the patients was 52.4 ± 1.4 years. 28(42.42%) of the studied patients were hypertensive and 22(33.33%) had diabetes. On chest radiographic findings, majority of the patients 57(86.4%) had bilateral consolidations. COVID PCR or COVID Rapid Antigen was positive in 56(84.0%) of the patients. The mean oxygen saturation on presentation was $93\% \pm 7.9$. 28(42.42%) of the patients had CRP levels < 5.0 mg/L,

while 30(45.45%) of the patients had CRP levels > 5.0 mg/L, with an insignificant difference between them ($p=0.78$). 24(36.36%) of the patients had D-dimer levels < 250 ng/ml, while 30(45.45%) of the patients had D-dimer levels > 250 ng/ml with significant difference between them ($p=0.025$), mean TLC count was found 7825 ± 3370 /microliter. 32 (48.5%) patients used to wear mask while 36(54.5%) patients used sanitizer. The mean baseline oxygen saturation in patients who used sanitizer was 94.7 ± 4.7 compared to 90.87 ± 10.3 in patients who did not use sanitizer with a significant difference between them ($p=0.05$), as shown in Table I.

All patients were given sucralfate and nimesulide, 16(24.24%) patients received enoxaparin while 49(74.24%) patients did not receive enoxaparin and found a significant difference between the mean change in oxygen saturation of them ($p=0.0001$). On the other hand, 47 (71.2%) patients received azithromycin while 19(28.8%) patients did not receive azithromycin and found a significant difference between the mean change in oxygen saturation of them ($p=0.03$). All patients were treated at home except for one patient who required intensive care support and hospitalization. One patient developed left bundle branch block and was referred for cardiac evaluation but managed conservatively. In 34 (51.52%) patients fever settled within 24 hours, in 62 (93.94%) patients, the fever settled within 3 days. The mean spO_2 after 5 days was 95.9 ± 3.0 , as shown in Table II.

RESULT

Table I: Demographic Characteristics of the study patients (n=66)

	Groups	Mean±SD Baseline SPO2	p-value
Gender	Male (n=35)	92.83±6.41	0.75
	Female (n=31)	93.13±9.39	
Age (years)	50 years or less (n=31)	93.94±9.4	0.64
	> 50 years (n=35)	92.11±6.25	
CRP (mg/L)	5.0 or less (n= 28) normal	93.4±10.15	0.78
	> 5.0 (n= 30) diseased	92.63±6.0	
D-Dimers (ng/mL)	250 or less (n=24)	95.25±3.91	0.025
	More than 250 (n=30)	92.57±5.92	
TLC (WBC/microliter)		7825±3.37	0.248
Use of Mask	Yes (n=32)	92.28±9.75	0.44
	No(n=34)	93.62±5.68	
Use of Sanitizer	Yes(n=36)	94.72±4.46	0.05
	No (n=30)	90.87±10.34	

Table II: Mean change in Oxygen Saturation with Nimesulide treatment after five days.

	Status	Mean±SD Change in SPO2	p-value
Oxygen Saturation	Baseline: 93%±7.9	3.2 % ±5.9	<0.001
Diabetes	Yes (n=22)	1.55±0.55	0.03
	No (n=44)	3.68±1.02	
Hypertension	Yes (n= 28)	2.29±0.7	0.233
	No (n= 38)	3.47±1.1	
Enoxaparin	Yes (n=16)	8.1±9.4	<0.001
	No (n=49)	1.36±2.46	
Azithromycin	Yes (n=47)	3.8±6.57	0.03
	No (n=19)	0.8±2.19	

DISCUSSION

Nimesulide is a powerful blocker of Interleukin 6 but effects mildly on Interleukin 8 levels.[27] Regardless of other procedures, it limits the development of TNF alpha (Tumor Necrosis Factor Alpha) and limits the formation of matrix metalloproteinases as well.[28] In a mice model of acute pancreatitis, Nimesulide-treated mice inhibited the progression of acute lung injury by restraining the activity of Interleukin 6, Interleukin 1B, and TNF alpha along with blocking the expression of the COX2 enzyme in lung tissues.[29] As far as our study is concerned; the role of nimesulide is significantly associated with the antipyretic activity by inhibiting the expression of COX2 enzyme in lung tissues of Covid-19 patients thereby decreases the inflammation of lungs. It also improved the oxygen saturation level.

In a retrospective analysis conducted in Wuhan, investigators assessed the clinical route of infection along with risk factors of COVID-19 infection. The survived patients in the study group had a fever that ended for around 12 days while 13 days in patients who died.[30] Persistent high grade fever in COVID-19 infection reflects the severity of the disease [31] and showed indication of inflammation indirectly. The use of nimesulide reduce the temperature at a considerably faster pace that showed its superiority over dexamethasone or tocilizumab because it impedes the inflammatory reaction by limiting the viremic phase or protecting the patient to develop super infections or other unfavorable side effects associated with the drugs.[31] In our study, nimesulides not only settled the fever within five days by impeding the activity of COX2 enzyme but also improved the oxygen saturation level. Hence, our study proved the superior activity of nimesulides over other NSAIDs.

Similarly, another research revealed that enoxaparin and azithromycin also has a wide range antiviral function against Respiratory syncytial virus, influenza H1N1, Ebola, Zika, rhinovirus, and enterovirus. [32] It has been observed to exhibits immunomodulatory characteristics in COVID-19 infection by its impeding action on numerous cytokines. It reduces the development of Interleukin-1B, Interleukin-6, Interleukin-8, Interleukin-10, Interleukin-12, and INF-alpha.[33] It was also observed in our study that patients treated with azithromycin and enoxaparin had a greater improvement in their oxygen saturation. Azithromycin is a macrolide antibiotic and is suggested for the treatment of respiratory tract bacterial infections. However,

azithromycin decreases the occurrence of overwhelming bacterial infection in already injured lungs.

One more research studied the role of Enoxaparin and heparin in covid 19 infection. Enoxaparin might decrease the probability of thrombosis and could be helpful in the management of COVID-related pulmonary vascular disease. Additionally, it reduces the levels of Il-6 and can possess least immunomodulatory property. Moreover, it is believed that limit the viral entrance into the cells resulting a lessening of viral load in blood.[34] Another retrospective analysis studied 1,113 patients in which clinical outcomes of Enoxaparin were assessed in comparison with other anticoagulants. Therefore, it was proved by the study that Enoxaparin significantly associated with the lower mortality rate.[35] Our study was also consistent with the above reported studies and revealed that administration of Enoxaparin significantly improved the coagulopathies associated with the Covid-19 infection thereby reducing the mortality rate.

Similarly, another researcher Lin et al. emphasized that the elevated inflammatory factors and D-dimer on days 7–14 of the infection might support anticoagulation with prescription of low molecular weight heparin (LMWH) as a remedial approach [36]. Concerns about the raised chances of disseminated intravascular coagulation (DIC) induced by sepsis, the researchers propose anticoagulation for COVID-19 infected patients with D-Dimer levels more than four folds the upper limit of normal (ULN), excluding those with contraindications to anticoagulation. They suggested a dose of 100 IU/kg of LMWH two times a day subcutaneously, for minimum 3–5 days [36]. Our study was inconsistent with the above mentioned study and reported that those patients had elevated D-dimer needed to prescribe subcutaneous dose of 60 mg of enoxaparin instead of heparin once daily as a therapeutic strategy in order to support anticoagulation for COVID-19 patients

Likewise, the European Society of Cardiology currently suggested an anticoagulation algorithm, [37] that defined the consideration of anticoagulation strategies. For elevated thrombotic risk patients elucidated with dyspnea, respiratory rate more than 24, oxygen saturation less than 90%, high CRP, raised D-dimer levels, and higher fibrinogen levels, are the good indicators for prescription of anticoagulants [37]. In the critical care settings, administration of heparin through parenteral route with close observation along with an active prothrombin time target of 60–85 s was recommended. For non-critical conditions, they advocate the dose of enoxaparin

1 mg/kg two times daily subcutaneously or suggested to follow the similar heparin injection for critical patients [37]. As far as our study is concerned, 30(45.45%) patients had elevated D dimer, 30(45.45%) patients had elevated CRP, and more than half patients had oxygen saturation < 90% along with diabetes and hypertension needed to prescribe azithromycin 250 mg twice daily along with enoxaparin in a dose of 60 mg subcutaneously once daily for five days.

The mixed approach of our study has assured that we have samples of an extensive range of patients with COVID-19 infection. However, the study might not be immune from observer and selection bias.

CONCLUSION

This study concluded that Nimesulide treatment resulted in a rapid defervescence i.e. temperature fall in three days. Furthermore, oxygen saturation was significantly improved in patients treated with azithromycin and enoxaparin. Moreover, our study suggested the administration of antibacterial macrolide and anticoagulation in COVID-19 patients who had elevated D-dimer levels and raised CRP levels.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly used products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

REFERENCES

1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med*. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764.
2. Gandhi RT, Lynch JB, del Rio C. Mild or moderate Covid-19. *N Engl J Med*. 2020 Oct 29;383(18):1757-1766. doi: 10.1056/NEJMcp2009249.
3. Wagner T, Shweta F, Murugadoss K, Awasthi S, Venkatakrishnan AJ, Bade S, et al. Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. *Elife* 2020 Jul 7;9:e58227. doi: 10.7554/eLife.58227.
4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. *JAMA*. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
5. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis*. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
6. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'cytokine storm' in COVID-19. *J Infect*. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037.
7. Berson A, Cazanave S, Descatoire V, Tinel M, Grodet A, Wolf C, Feldmann G, Pessayre D. The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxy methane-sulfoanilide), uncouples mitochondria and induces mitochondrial permeability transition in human hepatoma cells: protection by albumin. *J PharmacolExpTher*. 2006 Jul;318(1):444-54. doi: 10.1124/jpet.106.104125.

8. Bennett A, Vila D. Nimesulid - nesteroidnoprotivov'zpalitel'no lekarstvenosredstvo, preimyshestveninkhibitor COX-2 [Nimesulide - a non-steroidal anti-inflammatory drug, a preferential cyclooxygenase-2 inhibitor]. Vutr Boles. 2000;32(1):33-6. Bulgarian. PMID: 11195195.
9. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020 Oct;180:114147. doi: 10.1016/j.bcp.2020.114147. Epub 2020 Jul 10. PMID: 32653589; PMCID: PMC7347500.
10. McNaughton R, Huet G, Shakir S. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making. BMJ Open. 2014 Jan 15;4(1):e004221. doi: 10.1136/bmjopen-2013-004221.
11. Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancer medical science. 2020;14:1023. Published 2020 Mar 30. doi:10.3332/ecancer.2020.1023,
12. Bleyzac N, Goutelle S, Bourguignon L, Tod M. Azithromycin for COVID-19: More Than Just an Antimicrobial? Clin Drug Investig. 2020 Aug;40(8):683-686. doi: 10.1007/s40261-020-00933-3. PMID: 32533455; PMCID: PMC7290142.
13. Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, Sandoval-Espinosa C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci USA. 2016 Dec 13;113(50):14408-14413. doi: 10.1073/pnas.1618029113.
14. Tran DH, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara A, et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza (H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo). 2019 Oct;72(10):759-768. doi: 10.1038/s41429-019-0204-x.
15. Mosquera RA, De Jesus-Rojas W, Stark JM, Yadav A, Jon CK, Atkins CL, et al. Role of prophylactic azithromycin to reduce airway inflammation and mortality in a RSV mouse infection model. Pediatr Pulmonol. 2018 May;53(5):567-574. doi: 10.1002/ppul.23956.
16. Zeng S, Meng X, Huang Q, Lei N, Zeng L, Jiang X, et al. Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro

and in vivo. *Int J Antimicrob Agents*. 2019 Apr;53(4):362-369. doi: 10.1016/j.ijantimicag.2018.12.009.

17. Beigelman A, Isaacson-Schmid M, Sajol G, Baty J, Rodriguez OM, Legee E, et al. Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. *J Allergy Clin Immunol*. 2015 May;135(5):1171-8.e1. doi: 10.1016/j.jaci.2014.10.001.
18. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949.
19. Andreani J, Le Bideau M, Dufot I, Jardot P, Rolland C, Boxberger M, et al. In vitro testing of hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *MicrobPathog*. 2020;25(145):104228.
20. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. *Antimicrob Agents Chemother*. 1997 Jun;41(6):1399-402. doi: 10.1128/AAC.41.6.1399.
21. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *J ThrombHaemost*. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810.
22. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013.
23. Pawlowski C, Wagner T, Puranik A, Murugadoss K, Loscalzo L, Venkatakrishnan AJ, et al. Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC). *Elife* 2020 Aug 17;9:e59209. doi: 10.7554/eLife.59209.
24. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012 Feb;141(2 Suppl):e152S-e184S. doi: 10.1378/chest.11-2295.

25. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J ThrombHaemost*. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817.
26. Barco S, Bingisser R, Colucci G, Frenk A, Gerber B, Held U, et al. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. *Trials* 2020;21:770
27. Henrotin YE, Labasse AH, Simonis PE, Zheng SX, Deby GP, Famaey JP, et al. Effects of nimesulide and sodium diclofenac on interleukin-6, interleukin-8, proteoglycans and prostaglandin E2 production by human articular chondrocytes in vitro. *Clinical and experimental rheumatology*. 1999 Mar 1;17(2):151-60.
28. Pelletier JP, Martel-Pelletier J. Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. *Drugs*. 1993 Nov;46(1):34-9.
29. Yang Z, Ji W, Li M, Qi Z, Huang R, Qu J, et al. Protective effect of nimesulide on acute lung injury in mice with severe acute pancreatitis. *American journal of translational research*. 2019;11(9):6024.
30. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, *Lancet*. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3.
31. Gul MH, Htun ZM, Inayat A. Role of fever and ambient temperature in COVID-19. *Expert Rev Respir Med*. 2021 Feb;15(2):171-173. doi: 10.1080/17476348.2020.1816172.
32. Du X, Zuo X, Meng F, Wu F, Zhao X, Li C, et al. Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. *BiochemBiophys Res Commun*. 2020;522(4):862–8. DOI:10.1016/j.bbrc.2019.11.065.
33. Cai M, Bonella F, Dai H, Sarria R, Guzman J, Costabel U. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. *Immunobiology*. 2013;218(6):930–7.doi: 10.1016/j.imbio.2012.10.014.
34. Drago F, Gozzo L, Li L, Stella A, Cosmi B. Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current

Evidence. Frontiers in Pharmacology. 2020 Sep 16;11:1469.doi: 10.3389/fphar.2020.579886

35. Pawlowski C, Venkatakrishnan AJ, Kirkup C, Berner G, Puranik A, O'Horo JC, et al. Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients. *EClinicalMedicine*. 2021 Mar;33:100774. doi: 10.1016/j.eclinm.2021.100774. E
36. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection—a review of immune changes in patients with viral pneumonia. *Emerging Microbes & Infections*. 2020;9(1):727–732. doi: 10.1080/22221751.2020.1746199.
37. Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. *European Heart Journal - Cardiovascular Pharmacotherapy*. 2020;(pvaa036). 10.1093/ehjcvp/